IO Biotech Inc (IOBT)vsBeiGene, Ltd. (ONC)
IOBT
IO Biotech Inc
$0.19
-8.61%
HEALTHCARE · Cap: $12.71M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
IOBT
Avoid19
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IOBT.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 19.1x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : IOBT
IOBT has a balanced fundamental profile.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : IOBT
The primary concerns for IOBT are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
IOBT profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
ONC carries more volatility with a beta of 0.52 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 19/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IO Biotech Inc
HEALTHCARE · BIOTECHNOLOGY · USA
IO Biotech Inc. is a clinical-stage biotechnology firm focused on pioneering innovative immunotherapy solutions to bolster the immune response against cancer. Utilizing its novel immune-oncology platform, the company aims to stimulate and enhance the body’s innate defenses to target tumor cells. With a robust pipeline of therapeutic candidates progressing through clinical trials, IO Biotech is well-positioned to meet pressing unmet needs in oncology, particularly for solid tumors. The company's dedication to rigorous scientific research underscores its potential to transform the standards of cancer treatment and significantly improve patient outcomes.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?